-

Bruker Introduces Vutara™ VXL Best-in-Class Super-Resolution Microscope and Spatial Biology Analysis Capabilities

Accessible 3D Single-Molecule Localization Microscopy for Studying Subcellular Organelles and Spatial Multiomics

MADISON, Wisc.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the release of the Vutara VXL Super-Resolution Fluorescence Microscope for nanoscale biological imaging. The new system opens an affordable and easy-to-use path for both core facilities and individual investigators to enter the world of super-resolution imaging by incorporating Bruker’s industry-leading single-molecule localization (SML) technology in a streamlined system with compact footprint.

Vutara VXL serves as a biological microscopy workstation for research on DNA, RNA and proteins, from macromolecular complexes and super-structures, to chromatin structure and chromosomal substructures, to studying functional relationships in genomes and in various subcellular organelles. This novel system also supports advanced spatial biology research in extracellular matrix structures, extracellular vesicles (EV), virology, neuroscience, and live-cell imaging. When combined with Bruker’s unique microscope fluidics unit, Vutara VXL enables multiplexed imaging for targeted, sub-micrometer multiomics in genomics, transcriptomics, and proteomics research. The Vutara VXL software already supports leading-edge methods, such as OligoSTORM, Optical Reconstruction of Chromatin Architecture (ORCA), and DNA PAINT labeling methodologies.

“I am thrilled about the release of Vutara VXL, as this instrument is fundamental in making SML microscopy more accessible to the scientific community, and to the spatial 3D genomics research community in particular,” said Jennifer E. Phillips-Cremins, Ph.D., Associate Professor of Biotechnology and Genetics at the University of Pennsylvania. “Witnessing first-hand Bruker’s software and hardware development to enhance the spatial genomics capabilities that are required for my research bears testament to both their dedication and the functionality and versatility of the Vutara platform.”

“We believe that enabling 3D single-molecule localization microscopy in the hands of more researchers will further advance a better understanding of cellular biology at the nano level, particularly in the emerging field of spatial omics imaging,” added Xiaomei Li, Ph.D., Vice President and General Manager of Bruker’s Fluorescence Microscopy business. “Combined with its large field of view and ability to perform optical nanoscopy, Vutara VXL delivers multimodal capabilities and high-throughput data acquisition to enable a wider range of studies for spatially resolved genomics and transcriptomics.”

About Vutara VXL

Based on the Vutara super-resolution platform’s proprietary biplane technology, proven industry-leading capabilities with fully integrated fluidics with unlimited multiplexing potential, and powerful analytical software, the new Vutara VXL facilitates scientific research from experiment initiation and data collection through analysis to publication. The system enables researchers to obtain intrinsic 3D super-resolution data and achieve 20 nm localization precision in XY, 50 nm in Z for organic dyes, and even finer with DNA PAINT probes. A proprietary emission path allows the system to achieve low background fluorescence, even in thick samples, routinely imaging large Z volumes in tissue slices up to 30 µm in thickness at arbitrary distances from the coverslip. With the SRX software package and its Quantitative Localization Microscopy analysis suite, Vutara VXL facilitates the entire imaging process from acquisition and localization, and provides in-depth visual and quantitative information from biological samples in a single, seamless workflow. Utilizing real-time localization analysis and data visualization, multi-location recording capabilities, and scripting functions for automated data analysis, completion of an entire workflow cycle can be accomplished in a matter of minutes, providing a significant enhancement to work throughput. As a multi-modality workstation for single-molecule localization microscopy as well as conventional diffraction-limited widefield imaging, Vutara VXL is an ideal platform for bioinformatics, such as looking at the spatial distribution of the transcriptome in conjunction with high-resolution genomic or proteomic imaging.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investors:
Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Surfaces and Metrology Division
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Introduces Vutara™ VXL Best-in-Class Super-Resolution Microscope and Spatial Biology Analysis Capabilities
Release Versions

Contacts

Investors:
Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Surfaces and Metrology Division
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom